The latest price target for Aligos Therapeutics (NASDAQ:ALGS) was reported by HC Wainwright & Co. on November 7, 2024. The analyst firm set a price target for $75.00 expecting ALGS to rise to within 12 months (a possible 275.00% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Aligos Therapeutics (NASDAQ:ALGS) was provided by HC Wainwright & Co., and Aligos Therapeutics reiterated their buy rating.

The last upgrade for Aligos Therapeutics Inc happened on January 6, 2023 when Piper Sandler raised their price target to $3. Piper Sandler previously had a neutral for Aligos Therapeutics Inc.

The last downgrade for Aligos Therapeutics Inc happened on May 5, 2022 when SVB Leerink changed their price target from $7 to $3 for Aligos Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aligos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aligos Therapeutics was filed on November 7, 2024 so you should expect the next rating to be made available sometime around November 7, 2025.

While ratings are subjective and will change, the latest Aligos Therapeutics (ALGS) rating was a reiterated with a price target of $75.00 to $75.00. The current price Aligos Therapeutics (ALGS) is trading at is $20.00, which is out of the analyst’s predicted range.